Sindopa

Quick links to important sections

Sindopa

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sindopa

Quick Facts

Property Description
Active Ingredients Levodopa, Carbidopa
Form Oral Tablet (Immediate-release and extended-release)
Pharmacological Class Dopaminergic Antiparkinsonism Agent
General Purpose Dopamine Replacement Therapy
Origin Synthetic Combination Product

What is Sindopa and What Class Does it Belong To?

Sindopa, known generically as co-careldopa, is a prescription-only combination product administered as an oral tablet. This medication is classified as a dopaminergic antiparkinsonism agent, a therapeutic category of synthetic compounds designed to address chemical deficiencies in the brain related to movement control. The combination of its two active compounds is clinically recognized for providing a foundational pharmacological approach to manage specific neurochemical imbalances affecting motor function. While co-careldopa is the formulation, the brand name Sindopa is typically associated with various dosage formats, including immediate-release and controlled-release options (e.g., Syndopa CR).

Composition: Why is it a Combination of Carbidopa and Levodopa?

The drug's structure relies on the combination of Levodopa and Carbidopa in a single tablet format. Levodopa is the essential component, recognized as a prodrug and a direct metabolic dopamine precursor. Levodopa is transformed into Dopamine in the CNS. The inclusion of Carbidopa is a strategic necessity because it acts as a peripheral decarboxylase inhibitor, a compound that prevents the premature breakdown of Levodopa by enzymes outside the brain. This structure is designed to enhance the drug's access to the brain.

What is the General Purpose of Sindopa?

The overarching goal of using Sindopa is to provide specialized dopamine replacement therapy. Combining Levodopa with a peripheral decarboxylase inhibitor, like Carbidopa, is a standard pharmacologic approach for treating this specific chemical imbalance. By delivering and protecting the necessary precursor, the medicine supports the replenishment of the deficient neurotransmitter, which is the fundamental therapeutic strategy used to enhance the brain’s ability to regulate motor control and alleviate related movement difficulties.

Regulatory References

  1. NIH MedlinePlus Drug Information on Levodopa/Carbidopa

What side effects are possible with Sindopa?

Possible Side Effects and Safety Information

The safety profile of Sindopa (levodopa/carbidopa) is officially documented by regulatory authorities, classifying potential adverse reactions by frequency and physiological system. Dyskinesia (involuntary movements) and Nausea are classified as Very Common adverse reactions, often appearing during treatment. Other Common effects include orthostatic hypotension, hallucinations, insomnia, and confusion.


System-Organ Classes and Serious Adverse Reactions

Adverse effects are categorized into groups such as Nervous System Disorders (e.g., somnolence, dizziness), Psychiatric Disorders (e.g., psychosis, depression, impulse control disorders), and Gastrointestinal Disorders (e.g., vomiting, constipation). Serious adverse reactions documented in official labels include a risk of withdrawal-emergent hyperpyrexia and confusion if the medication is suddenly stopped or the dose is rapidly reduced. Additionally, the drug has been associated with an increased risk of developing malignant melanoma.


Safety Considerations and Restrictions

Safety notes specify that effects like motor fluctuations may be observed during long-term therapy. The medication is formally contraindicated in patients with a history of malignant melanoma or suspicious skin lesions, and in those with narrow-angle glaucoma. Caution is also specified for special populations, as safety and effectiveness have not been established in patients under 18, and cautious use is necessary in patients with severe renal or hepatic disease.

Overdose and Emergency Response

Sindopa Overdose and when to seek help

The following information is derived strictly from government regulatory documentation, detailing the officially documented manifestations and required emergency actions for Sindopa (Levodopa/Carbidopa) overdose.

Overdose Risk Area Officially Documented Manifestations and Actions
Clinical Presentation Overdose symptoms are typically driven by excessive peripheral dopaminergic activity. Manifestations may include pronounced involuntary movements (dyskinesias), agitation, confusion, insomnia, and the appearance of reddish-brown or dark urine.
Severe Outcomes The official labeling documents the risk of severe cardiac arrhythmias (such as sinus tachycardia or atrial fibrillation) and clinically relevant profound hypotension. These findings require immediate intervention.
Emergency Action Seek immediate medical attention for the management of any suspected overdose. Emergency services must be contacted immediately if symptoms of cardiac involvement or severe neurological changes are present.

Management and Monitoring

Management of overdose is defined as symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known. The official procedure requires intensive cardiac monitoring using ECG and continuous observation of the cardiovascular system. Specific supportive measures listed include the potential consideration of gastric lavage in acute settings, the use of antiarrhythmic agents to manage cardiac issues, and the administration of intravenous fluids for hypotension. Regulatory documents also note an increased risk of cardiac arrhythmias in patients with pre-existing cardiovascular disease following an overdose.

Therapeutic Uses of Sindopa

What Sindopa Treats: Main Uses and Benefits

Sindopa (levodopa/carbidopa) is commonly used for the symptomatic management of Parkinson's disease and related syndromes. The medication is applied in situations involving symptoms that create noticeable physiological strain, generally targeting symptoms of increased neurological or muscular activity that are characteristic of the condition. These conditions include idiopathic Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow specific intoxications (e.g., carbon monoxide).

The medication helps address symptom clusters that may become intense or disruptive, such as pronounced slowness of movement (bradykinesia), significant muscle rigidity (stiffness), and unwanted resting tremor. The treatment contributes to easing the overall symptom load, which may assist with maintaining functional stability and coordination, particularly when symptoms become more disruptive during flare-ups.

“It provides supportive relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Motor Symptoms
Symptom Domain Bradykinesia, Rigidity, Tremor
Clinical Context Chronic Neurodegenerative Management
Patient Benefit Supports functional independence and day-to-day comfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Sindopa?

The eligibility for Sindopa (levodopa/carbidopa) is governed by official regulatory criteria regarding a patient's age and existing medical conditions.

Populations Contraindicated

Use is absolutely prohibited in patients with a history of melanoma or undiagnosed suspicious skin lesions, individuals with narrow-angle glaucoma, and those with a known hypersensitivity to any component of the formulation. It is also contraindicated for patients currently taking nonselective Monoamine Oxidase (MAO) inhibitors; these must be discontinued two weeks prior to starting treatment. Some regulatory sources also list severe hepatic impairment and phaeochromocytoma as contraindications.

Age and Reproductive Status

Sindopa is indicated only for adult patients; its safety and efficacy have not been established in children under 18 years of age, and use is not recommended. Due to a lack of adequate human data, the medicine is generally not recommended during pregnancy or while breastfeeding, as levodopa is known to be excreted into human milk.

Conditional Use and Restrictions

The medicine must be administered with caution and monitoring to patients with specific conditions, including severe renal or hepatic impairment, certain residual cardiac arrhythmias, a history of peptic ulcer disease, or a major psychotic disorder.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Sindopa (levodopa/carbidopa) is defined by mandatory regulatory restrictions, pharmacokinetic interference, and pharmacodynamic effects, all documented in official labeling.

Formal Contraindications and Restrictions Co-administration with Nonselective Monoamine Oxidase (MAO) Inhibitors is formally contraindicated due to the risk of hypertensive crisis. These agents require a mandatory two-week washout period before Sindopa therapy can be initiated. Selective MAO Type B Inhibitors may be administered concomitantly only at the manufacturer's recommended doses.

Pharmacokinetic Interactions Interactions involving absorption and bioavailability are documented with specific substances:

  • Iron Salts and iron-containing products reduce the oral bioavailability of levodopa and carbidopa. This chelation interaction requires that administration be separated by as much time as possible.
  • High Protein Meals interfere with levodopa absorption and transport by fostering competition from Large Neutral Amino Acids (LNAAs) for the active transport system.

Pharmacodynamic Interactions The label specifies functional interactions with certain drug classes:

  • Antihypertensive Agents may result in additive hypotensive effects.
  • Antipsychotic Agents (including phenothiazines and butyrophenones), Phenytoin, and Papaverine may reduce the therapeutic effect of levodopa through documented receptor blocking or functional antagonism.

Mechanism of Action

Peripheral Enzyme Inhibition and CNS Precursor Delivery

This mechanism relies on a synergistic action at the enzyme level to support the full activation of the central mechanism. The active component, Levodopa, must cross the Blood-Brain Barrier (BBB) to function, but it is rapidly broken down in the bloodstream by the enzyme AADC (Aromatic-L-Amino-Acid Decarboxylase). The second component, Carbidopa, acts as an irreversible inhibitor of AADC exclusively in the periphery, limiting the peripheral breakdown of Levodopa. This process increases the fraction of the precursor molecule available for transport into the Central Nervous System via the LAT1 transporter, a required step that dictates the amount of precursor available for central conversion.


Central Conversion and Dopamine Receptor Activation

Once inside the CNS, the protected Levodopa is converted by remaining AADC enzymes into the active neurotransmitter, Dopamine. This replenished dopamine acts as a functional agonist at central Dopamine Receptors (D1, D2, etc.) within the nigrostriatal pathway, which is integral to the brain's motor control circuitry. Activation of these receptors modulates the signaling patterns of the basal ganglia. This modulation of the basal ganglia signaling patterns is the physiological consequence of central dopamine receptor activation.


Constraints on Mechanism Consistency

The efficacy of this replacement mechanism is inherently limited by the progressive loss of intrinsic dopaminergic neurons, as these cells are necessary to execute the final conversion and storage of dopamine. Furthermore, Levodopa must compete with large neutral amino acids from the diet for transport across both the gut and the BBB. These physiological constraints influence the temporal consistency of the resulting receptor activation.

Dosage and Administration Information

Sindopa, known generically as co-careldopa, is administered via two approved routes: oral (using immediate-release, extended-release, or orally disintegrating tablets) and enteral infusion for continuous delivery in advanced cases.

The standard administration protocol involves a titration phase, beginning with a low daily amount, such as 25 mg carbidopa / 100 mg levodopa, typically administered three times per day (TID). The dosage is then gradually increased over a series of days or weeks until the optimal balance is established. The total daily carbidopa dose generally should not exceed 200 mg.

Dosing Frequency and Special Handling

The frequency of administration depends on the formulation, with immediate-release tablets usually taken three to four times a day. The extended-release forms, designed for prolonged effect, typically require administration two to five times per day with multi-hour intervals. The medicine may be taken with or without food; however, consumption alongside high-fat, high-calorie meals may delay the time it takes for the drug to be absorbed.

Regarding preparation, all extended-release tablets and capsules must be swallowed whole and must not be crushed, divided, or chewed, as this alters the intended release mechanism. Furthermore, dosages of immediate-release and extended-release forms are not interchangeable on a one-to-one milligram basis. The overall protocol is designed for long-term management, and special consideration is given to specific populations, such as older adults, for whom dosage reduction may be necessary.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Sindopa (Levodopa/Carbidopa)


Evidence for Management of Idiopathic Parkinson's Disease Symptoms

Research for levodopa/carbidopa includes a large volume of data focusing on patients with idiopathic Parkinson's disease. This evidence primarily comes from Randomized Controlled Trials (RCTs) and systematic reviews, which were used in research exploring how core motor symptoms change over time. Studies primarily examined changes in scores on scales related to bradykinesia (slowness of movement) and rigidity (stiffness).

Foundational research examined symptom patterns when comparing the combination of levodopa and carbidopa to levodopa used alone. The research provides data on initial motor control and symptom patterns in the populations studied. While short-term data is available, the earliest pivotal research for the immediate-release formulation may differ from today's current standards for study reporting, and long-term research is often limited to observational data rather than controlled trials.


Research into Advanced Disease and Motor Fluctuations

For patients with advanced Parkinson's disease who experience significant variability in their symptoms, such as motor fluctuations or "wearing-off" episodes, research has explored specialized delivery systems. This research involved RCTs that compared continuous delivery methods (e.g., intestinal gel) against optimized oral regimens. Studies monitored outcomes related to the average daily time patients spent in the rigid, immobile "Off" state.

Findings indicate that certain continuous delivery methods were associated with specific patterns measured in the "Off" time outcomes in these advanced populations. However, trial populations were small in some specialized trials, meaning results apply only to the specific populations studied. Comparative evidence directly assessing different continuous delivery systems against each other is often lacking in the current research literature.


Where Research Gaps and Uncertainty Remain

Synthesis of the available evidence highlights areas where knowledge is still developing. Research has explored symptom intensity or variability, but the impact on certain non-motor symptoms, such as mood or sleep disturbances, requires further investigation. Additionally, research to date has not fully established whether the use of the medicine modifies the long-term underlying progression of the disease.

Key Studies & References

  1. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis (Advanced Disease/Fluctuations)
  2. Parkinson disease - WHO Model List of Essential Medicines (EML) Entry
  3. Motor fluctuations and dyskinesia in Parkinson disease (Clinical Overview)

Frequently Asked Questions (FAQ)

Common questions about Sindopa (FAQ)

Q: How quickly does Sindopa start working after taking a dose?

According to official product information, the active component of the immediate-release formulation typically reaches its maximum concentration in the bloodstream within 20 to 50 minutes after a dose. This measurement is used in pharmacological studies to indicate the time needed for the active component to reach its peak concentration in the bloodstream.

Q: How long does the effect of a single dose of Sindopa typically last?

Official information indicates the clinical effect for immediate-release tablets generally lasts for three to four hours. The specific duration of effect can vary between individuals and formulations.

Q: Is Sindopa the same as other levodopa-carbidopa medications, or are there differences?

Sindopa is a brand name for the combination drug levodopa/carbidopa, also known generically as co-careldopa. Official documents caution that the various available formulations, such as immediate-release and extended-release tablets, are not interchangeable on a one-to-one milligram basis.

Q: Can Sindopa be used by people who are not diagnosed with Parkinson's disease?

Official regulatory documents state that Sindopa is formally indicated for the treatment of the signs and symptoms of Parkinson's disease, including the most common type, idiopathic Parkinson's. Use is restricted to the specific conditions for which the drug has regulatory approval.

Q: Do initial side effects, like nausea or dizziness, eventually go away as the body adjusts to Sindopa?

Regulatory information indicates that certain gastrointestinal side effects, such as nausea, may be minimized. This is often achieved by ensuring adequate daily amounts of carbidopa or by taking the medication with a small, non-protein amount of food. These effects are often addressed during the initial period when the dosage is gradually adjusted.

Q: What is the 'wearing off' effect, and is it a normal part of using Sindopa?

'Wearing off' is a term used to describe motor fluctuations, a phenomenon where motor symptoms return or worsen toward the end of a dosing interval. Official product information notes that these motor fluctuations are reported during prolonged levodopa therapy and represent a change in response over time.

Q: Can Sindopa affect the results of certain laboratory tests?

Yes, official documents mention that Sindopa may affect the results of certain laboratory tests. This includes a possible false-positive result for ketones in the urine. It may also lead to a false-negative result when specific methods are used to test for glucose in the urine.

Q: Does the body build up a 'tolerance' to Sindopa over time?

While the drug is not typically described with the term 'tolerance,' official information does note that changes in response can occur over time. The development of dyskinesia (involuntary movements) and motor fluctuations are commonly observed adverse reactions after prolonged therapy.

Q: Is Sindopa associated with any long-term effects on cognitive function or memory?

Regulatory documents list psychiatric effects that can impact cognitive health, such as confusion, psychosis, and hallucinations, as common or serious adverse reactions. The primary long-term psychiatric effects documented are related to psychosis, confusion, and impulse control.

Q: Can Sindopa be used by people with a history of heart problems or heart attack?

Official regulatory warnings state that the medicine carries a caution for individuals who have a history of myocardial infarction (heart attack). Caution is also advised for patients with certain types of cardiac arrhythmias (irregular heart rhythms).

Q: What is the role of Sindopa in treating the non-motor symptoms of the condition?

The primary therapeutic purpose of Sindopa, based on its formal indication, is to address the signs and symptoms of impaired motor function. While research has explored the drug's impact on certain non-motor symptoms, such as mood and sleep, the official label does not specify a formal therapeutic role for these non-motor aspects.

Q: Does Sindopa help specifically with tremor, stiffness, or both symptoms?

The official indication for Sindopa is to treat the core signs and symptoms of Parkinson's disease. These symptoms include tremor, rigidity (stiffness), and bradykinesia (slowness of movement).

Q: Can taking Sindopa cause a person to fall asleep suddenly during the day?

Yes, official warnings note that patients treated with the drug have reported experiencing excessive somnolence (drowsiness). In some cases, patients have reported the experience of sudden sleep onset while engaged in daily activities.

Q: Is it possible for Sindopa to make sleep problems worse?

Official documents list insomnia (difficulty sleeping) as a common adverse reaction. The medicine is associated with various psychiatric symptoms, and insomnia (difficulty sleeping) is listed as a common adverse reaction.

Q: Is dizziness or lightheadedness a common initial experience with Sindopa?

Orthostatic hypotension, which causes dizziness or lightheadedness when standing up, is listed as a common adverse reaction. This effect is often observed during the initial dose titration period as the body adjusts to the medicine.

Q: How is the amount of carbidopa determined in the Sindopa combination product?

Regulatory documents state that a certain daily amount of carbidopa is necessary to inhibit the peripheral enzyme that breaks down levodopa outside the brain. This ensures more levodopa reaches the brain and helps minimize gastrointestinal side effects.

Q: What symptoms indicate a possible serious adverse reaction to Sindopa?

Serious adverse reactions that require urgent attention include the potential for withdrawal-emergent hyperpyrexia (high fever) and profound confusion if the drug is suddenly stopped. Official warnings also highlight the risk of malignant melanoma.

Q: Can Sindopa affect a person's judgment or coordination?

Yes, official warnings note that side effects such as drowsiness and dizziness may occur. This can impair the ability to perform tasks that require quick reaction and good judgment, such as driving or operating heavy machinery.

Q: Can Sindopa worsen pre-existing mental health conditions like depression?

The official label includes warnings that the medication can be associated with psychiatric symptoms such as depression and psychosis. Caution is advised for patients with a history of a major psychotic disorder, as the medicine may exacerbate or worsen these existing conditions.

Q: What should be done about the dark color Sindopa can cause in sweat or urine?

The drug may cause body fluids, including sweat, urine, or saliva, to turn a dark color (red, brown, or black). This known effect is documented in patient information and may potentially stain garments.

Q: Is it possible for Sindopa to cause increased feelings of anxiety or nervousness?

Yes, official documents list anxiety as a common adverse reaction under psychiatric disorders.

Q: Is Sindopa considered to be a 'stimulant' medication?

No, Sindopa is not classified as a stimulant. Instead, it is classified as a dopaminergic antiparkinsonism agent.

Q: Are there any known interactions between Sindopa and alcohol consumption?

Official regulatory information warns that alcohol can increase certain side effects related to the nervous system, such as drowsiness and dizziness. Alcohol may also potentially exacerbate orthostatic hypotension (low blood pressure when standing).

Q: Is it true that Sindopa is considered the 'gold standard' for this condition?

Regulatory sources state the drug is a foundational component of pharmacological management for the condition, used to provide dopamine replacement therapy. It is clinically recognized as an important therapeutic option.

Q: Are there different brand names that contain the same active ingredients as Sindopa?

Yes, the active components of Sindopa—levodopa and carbidopa—are also available under the generic name co-careldopa. These ingredients are also used in various other brand-name formulations.

Q: Can a person take Sindopa with non-protein snacks to help with nausea?

Nausea is listed as a common side effect. While the medicine can be taken with or without food, official documents suggest taking it with a small amount of food to help minimize general gastrointestinal upset. Official documents specify that high-protein meals can interfere with the absorption of the drug.

Q: What does the research evidence suggest about the use of Sindopa in the long term?

Official regulatory documents note that after prolonged use, the medicine is associated with the potential development of dyskinesia (involuntary movements). The development of motor fluctuations, commonly called 'wearing off,' is also noted as a complication that can arise with prolonged therapy.

How should Sindopa be stored and disposed of?

Storage and Disposal Requirements

Official instructions for carbidopa and levodopa are specific to the formulation. Both the oral tablets and the enteral suspension must be kept out of the sight and reach of children.


Oral Tablets

The tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). They must be dispensed and stored in a tight, light-resistant container. Unused or expired tablets should be discarded using an official drug take-back program or by following FDA household disposal guidelines.


Enteral Suspension (Cassette)

The cassettes must be stored in the refrigerator (2 C to 8 C) and must not be frozen. Before administration, the cassette requires handling to sit at room temperature for 20 minutes. The cassette is for single-use only and must be disposed of after a maximum of 16 hours of use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sindopa found in:

A-Z Index: